Low-Density Lipoprotein Receptor-Mediated Lipidome-Transcriptome Reprogramming Impulses to Cisplatin Insensitivity
W.-C. Chang, H.-C. Wang, W.-C. Cheng, J.-C. Yang, W.-M. Chung, L. Chen, Y.-P. Ho, Y.-C. Hung, W.-L. Ma
This study identifies LDLR-mediated lipidome-transcriptome reprogramming as a mechanism for cisplatin insensitivity in ovarian cancer and demonstrates a lipid-based drug delivery strategy to enhance chemotherapy efficacy.
bioRxiv · Dec 21, 2018 · PreprintCancer Biology